Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Darifenacin, ATC G04BD10

Health · Germany government procurement

GlobalGov surfaces government procurement from around the world, including the markets your competitors overlook.

April 30, 2027
Response Due
Active
Status

Opportunity Overview

Germany – Pharmaceutical products – Open house drug discount contracts for the active ingredient Darifenacin, ATC G04BD10

This Germany Pharmaceuticals opportunity is one most of your competitors will never see.

How to bid: GlobalGov tracks this tender; it does not accept bids. Submit your response through the issuing agency’s official notice.

Your competitors are watching the same crowded contracts everyone else is. Track this opportunity and every one like it worldwide, set deadline alerts, and win where they aren’t. Free for 14 days, no card.

Start a free GlobalGov account

Solicitation Details

Issuing agencyHealth
CountryGermany
CategoryPharmaceuticals
PublishedMay 19, 2025
Procurement stageActive solicitation
Response dueApril 30, 2027
StatusOpen — accepting responses
Original languageGerman — members read it in their own language
Official sourceView original notice
Last verifiedOctober 11, 2026

Source: Tenders Electronic Daily (TED), © European Union. Notice content reused under Commission Decision 2011/833/EU; editorial content licensed CC BY 4.0. GlobalGov is not affiliated with the European Union.

Related Opportunities in Germany

Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130 a Abs. 8 SGB V mit dem Wirkstoff Mycophenolsäure in der Darreichungsform PSE.
Germany – Pharmaceutical products – Abschluss eines nicht exklusiven Rabattvertrages nach § 130a Abs. 8 SGB V zu Arzneimitteln mit der Wirkstoffkombination aus Brinzolamid und Brimonidin (ATC-Code: S01EC24).
Germany – Pharmaceutical products – Arzneimittel mit dem Wirkstoff Infliximab (ATC: L04AB02 - in der Darreichungsform Injektionslösung)
Germany – Pharmaceutical products – Arzneimittel mit der Wirkstoffkombination Metoprolol und Hydrochlorothiazid (ATC: C07BB22)
Germany – Pharmaceutical products – Arzneimittel mit dem Wirkstoff Leuprorelin (ATC: L02AE02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ambrisentan (ATC-Code nach WHO: C02KX02)
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Rivaroxaban Filmtabletten, ausgenommen in der Wirkstärke 2,5 mg, ATC B01AF01
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Clonidin, ATC C02AC01

See every Germany Pharmaceuticals opportunity your competition is missing. Free for 14 days.

Get real-time alerts, competitive intelligence, and deadline tracking for this and every market worldwide.

Start Free Trial — No Card Required

Free 14-day trial · no card required

See who is already competing here →

Get a free Germany Pharmaceuticals intelligence report in your inbox

A personalized report on Germany Pharmaceuticals opportunities, emailed in 5-10 minutes. One per month, no account needed.